Pan-TEAD Inhibitor ODM-212

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable non-covalent small molecule inhibitor of the TEA domain (TEAD) family of transcription factors, including TEAD1, TEAD2, TEAD3 and TEAD4, with potential antineoplastic activity. Upon oral administration, pan-TEAD inhibitor ODM-212 reversibly binds to the TEAD palmitoylation site and inhibits TEAD, thereby disrupting the interaction between the transcription co-activators yes-associated protein 1 (YAP)/WW domain-containing transcription regulator protein 1 (TAZ; transcriptional coactivator with PDZ-binding motif) and TEAD. This inhibits YAP/TAZ-TEAD-promoted transcription of multiple genes involved in tumor cell proliferation, progression and survival, and may result in enhanced apoptosis in TEAD-dependent cancers. Hippo pathway alterations, as seen in tumors with neurofibromatosis type 2 (NF2)-deficiency, large tumor suppressor 1 (LATS1) and 2 (LATS2) mutations and YAP/TAZ fusions, lead to Hippo pathway activation, hyperactivation of YAP/TAZ and activation of TEAD. It plays a key role in cancer initiation, progression, and cancer cell resistance to various therapies.

**Synonyms:** - ODM 212 - ODM-212 - ODM212 - TEAD Inhibitor ODM-212